McKesson dropped an interesting nugget in its earnings call yesterday: The drug distributor expects to spend $150 million defending itself in state and national opioids lawsuits in its 2021 fiscal year, which starts next March, up from more than $100 million this year.
Between the lines: $150 million is a rounding error for McKesson, which handled $214 billion of revenue last year. But the company is essentially breaking even these days, and those legal costs could go up by billions of dollars if a settlement is reached.
Go deeper: FDA blasts McKesson for not monitoring opioid shipments
